

Sacituzumab govitecan IMMU-132-01

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Sacituzumab govitecan IMMU-132-01

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease  
 Experimental Arm: Sacituzumab govitecan  
 Control Arm: Single arm (Phase I/II)

